Peptide Database

Peptide NameD-MART-1

Function Ontology

Anticancer

Binding / Molecular interaction ▸ Binding activity

Immunology ▸ Immunomodulation ▸ Immunogenic

Immunology ▸ MHC/HLA binding

Standard StatusStandard

Sequence Length9 amino acids

Chemical FormulaC37H67N9O11

DescriptionStandard

        AAGIGILTV
    

Molecular Weight813.98 Da

Isoelectric Point (pI)5.57

Net Charge (pH 7.0)-0.20

Net Charge (pH 7.4) -0.39

Charge Density (pH 7.0) -0.0227

GRAVY Index2.12

Hydrophobic Moment 0.08

Boman Index0.78

Instability Index11.42

Aliphatic Index 184.44

Aromaticity 0.0000

Extinction Coeff. Reduced 0.00

Extinction Coeff. Oxidized 0.00

The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.

Amino Acid Composition

TPSA 316.35

LogP -2.25

H-bond Donors 11.0

H-bond Acceptors 11.0

Rotatable Bonds 25.0

Heavy Atoms 57.0

Ring Count 0.0

Amide Bonds 8.0

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.

2D CHEMICAL STRUCTURE

Drag to move

Drag to move. Use the buttons to zoom.

RECORD: Rec_0028047 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyMART-1

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitymixed L/D amino-acid peptide [Mixed]

Other ModsD-Ala at 1st position, D-Val at 9th position

Bio-Activity Profile

Function

Anticancer

Targetfresh normal human plasma; MART-1-reactive cytotoxic T lymphocytes

Methodplasma proteolysis stability and CTL recognition assay

Half-LifeHuman plasma: Stability increased

PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/

RECORD: Rec_0055079 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermNone

C-TermPEGylation

Other ModsC-terminal PEGylation; PEGylation

Bio-Activity Profile

Function

Immunogenic HLA-binding

TargetHLA-A*0201

Activity>35 μM

MethodIC50 (competitive HLA-A*0201 binding assay)

Half-LifeVMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; Stability increased seconds

RECORD: Rec_0062555 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyMART-1

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermAcetylation

Other ModsN-terminal acetylation

Bio-Activity Profile

Function

Anticancer

Targetfresh normal human plasma; MART-1-reactive cytotoxic T lymphocytes

Methodplasma proteolysis stability and CTL recognition assay

Half-LifeHuman plasma: Stability increased

PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/

RECORD: Rec_0084394 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

N-TermAcetylation

C-TermAmidation

Other ModsN-terminal acetylation; C-terminal amidation; N-terminal acetylation; C-terminal amidation

Bio-Activity Profile

Function

Immunogenic HLA-binding

TargetHLA-A*0201

Activity65 μM

MethodIC50 (competitive HLA-A*0201 binding assay)

Half-LifeVMM5 cytotoxic T-lymphocyte line incubated in human plasma, in vitro; Stability increased seconds

RECORD: Rec_0103440 VERIFIED: YES

Provenance & Taxonomy

Organismsynthetic construct [Synthetic]

FamilyMART-1

Tax ID32630

Structure & Mods

Configlinear peptide [Linear]

Chiralitycanonical L-amino-acid peptide [L]

Bio-Activity Profile

Function

Anticancer

Targetfresh normal human plasma

Activity22 s

Methodplasma half-life

Half-LifeHuman plasma: Half-life is 22 s

PaperBrinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999 Oct 29;83(3):326-34. PMID:10495424 https://pubmed.ncbi.nlm.nih.gov/10495424/ PMID10495424 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/10495424/

1 2 3 NEXT LAST

Showing 5 records · Page 1 of 3